Artificial intelligence (AI) software developer RapidAI has secured U.S. Food and Drug Administration (FDA) 510(k) clearance for its Rapid RV/LV software.
Available as part of the firm's Rapid PE detection and analysis software for suspected cases of pulmonary embolism (PE), the RV/LV software automatically calculates an important indicator of PE severity -- the ratio between the right and left ventricles -- on CT pulmonary angiograms, RapidAI said. Results are available within minutes, enabling care teams to more quickly prioritize patients and speed up decision-making, according to the vendor.
